The clinical validity of the biomarker for the adjuvant chemotherapy in patients after curative resection for advanced gastric cancer

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10114
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Iwate Medical University
• Principal Investigator: Koeda Keisuke 岩手医科大学, 医学部, 教授 (10285596)
• Co-Investigator(Kenkyū-buntansha): 西塚 哲 岩手医科大学, 医学部, 教授 (50453311)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 胃癌 / 術後補助化学療法 / バイオマーカー / Helicobacter Pylori

Outline of Final Research Achievements

From 13 institutes, we accumulated a retrospective cohort of 654 patients. We gave up the the NF-κB/JNK immunostaining, because we could not available the antibody of NF-κB/JNK immunostaining which we planned. So we switched an idea to existence of chronic inflammation to bring about activation of NF-κB and examined a correlation of H. pylori and prognosis. With the score-matched 222 patients in 2 groups (i.e, "surgery" or "surgery + S-1"), 5-year overall survival rate was 62% and 62% in H. pylori-positive or negative patients in surgery group; while 72% and 62% in H. pylori-positive or negative patients in S-1 group. These results indicate that the point of effect of H. pylori infection in gastric cancer treatment is chemotherapy. These clinical and epidemiological data including ourselves led us to formulate the following aims to clarify the immunological mechanisms to drive better outcome in the challenging gastric cancer treatment.

Free Research Field

消化器外科、化学療法